Appeals Court Rules in Favor of Merck
A recent report confirmed that Merck & Co. (MRK) has managed to get a US appeals court ruling in its favour, which would prohibit Mylan Inc. (MYL) from selling a generic version of the Zetia and Vytorin cholesterol medicines before April 2014 when the patent expires.
It was claimed that Mylan had approached the U. S. Court of Appeals for the Federal Circuit in Washington over patenting the active ingredient in the drug, ezetimibe. "The appellate court appropriately upheld the lower court's ruling in April 2012 that found the patent for Zetia and Vytorin is valid and enforceable", said Ron Rogers, a Merck spokesman.
If reports are to be believed, Zetia generates as much as $1.33 billion while Vytorin ropes in $764 million. However, sales of Vytorin of late have been going down due to its ineffectiveness in dealing with the cases.
Moreover, the spokesperson has gone onto say that they would keep on investing time and money in research and development, in order to come out with better and better drugs and there would be no compromise made whatsoever in defending their intellectual property rights. Mylan has not responded to the decision made by the .S. appeals court on Thursday.
New Zealand News
- First deliveries of all-electric Porsche in Australia to take place this weekend
- Crown Resorts suffers record six-month loss due to COVID-19 closures
- Australia’s Crown Resorts 'not suitable' for Sydney gaming license: Inquiry Commission
- What Does Phasing Out Cheques Tell Us About Finance in New Zealand?
- South Korean casino operator GKL closes third casino amid soaring cases of COVID-19